Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56.1M
-
Number of holders
-
1
-
Total 13F shares, excl. options
-
38.9K
-
Shares change
-
+27.6K
-
Total reported value, excl. options
-
$109K
-
Value change
-
+$77.6K
-
Number of buys
-
1
-
Price
-
$2.81
Significant Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q4 2023
1 filings reported holding BDTX - Black Diamond Therapeutics, Inc. - Common Stock as of Q4 2023.
Black Diamond Therapeutics, Inc. - Common Stock (BDTX) has 1 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38.9K shares
of 56.1M outstanding shares and own 0.07% of the company stock.
Largest 10 shareholders include Bellevue Group AG (8.54M shares), NEA Management Company, LLC (4.45M shares), T. Rowe Price Investment Management, Inc. (3.93M shares), RA CAPITAL MANAGEMENT, L.P. (3.53M shares), Artal Group S.A. (2.05M shares), VANGUARD GROUP INC (1.95M shares), TANG CAPITAL MANAGEMENT LLC (1.8M shares), Verition Fund Management LLC (1.55M shares), BlackRock Inc. (1.35M shares), and JPMORGAN CHASE & CO (822K shares).
This table shows the top 1 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.